Vastan

Quick links to important sections

Vastan

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vastan

Property Description
Active Ingredient Simvastatin
Form Film-coated tablet
Pharmacological Class HMG-CoA Reductase Inhibitor (Statin)
Common Use Cholesterol-lowering therapy; Dyslipidemia management
Origin Semi-synthetic prodrug

1. What is Vastan and What Class Does It Belong To?

Vastan is a prescription-only medication whose active component, Simvastatin, classifies it as an HMG-CoA Reductase Inhibitor, a drug type commonly known as a statin. This substance is a member of the established family of lipid-modifying agents and is supplied as film-coated tablets for oral administration.

Simvastatin is a semi-synthetic prodrug, meaning the compound is derived from a natural substance but requires the body, typically the liver, to convert it into its fully active therapeutic form. The medicine is a single active ingredient product that is clinically recognized for the management of elevated lipid levels.

2. Simvastatin: Composition, Form, and General Purpose

The core mechanism of Vastan is the specific, competitive inhibition of HMG-CoA reductase, which is the critical, rate-limiting enzyme in the body's internal cholesterol synthesis pathway. By blocking this production process, Simvastatin reduces the concentration of self-generated cholesterol.

This action consequently lowers the concentration of low-density lipoprotein cholesterol (LDL-C), often termed "bad cholesterol". The general purpose of this cholesterol-lowering therapy is to support the long-term maintenance of a healthier lipid profile for adult patients and aid in the management of cardiovascular risk factors.

Regulatory References

  1. HMG-CoA Reductase Inhibitors - MedlinePlus
  2. LDL: The 'Bad' Cholesterol - MedlinePlus

What side effects are possible with Vastan?

Possible Side Effects and Safety Information

Vastan's safety profile, established through clinical trials and post-marketing surveillance, is focused on the potential for muscle and liver toxicity. Active liver disease or unexplained, persistent elevations in hepatic transaminases are formal contraindications.

Serious and Clinically Significant Adverse Reactions

The most serious documented risk is Rhabdomyolysis, a rare but potentially life-threatening muscle breakdown that can lead to acute renal failure. The risk of this adverse effect increases with higher doses and when Vastan is taken concomitantly with certain medications, such as strong CYP3A4 inhibitors. Persistent elevations of liver enzymes (hepatic transaminases) may also occur, indicating potential Hepatotoxicity that necessitates therapeutic discontinuation.

Common and Other Adverse Reactions

Commonly reported adverse reactions include nasopharyngitis, arthralgia (joint pain), diarrhea, and urinary tract infection. Post-marketing reports have also identified cognitive impairment (e.g., memory loss, confusion) as a generally non-serious and reversible side effect.

Population-Specific Restrictions and Caution

Vastan is formally contraindicated during pregnancy and in nursing mothers due to the potential for fetal harm. Caution is advised for patients with predisposing factors for muscle injury, including advanced age (over 65 years), uncontrolled hypothyroidism, and renal impairment. Liver enzyme testing is required before initiating therapy and as clinically indicated, and patients must be monitored for signs and symptoms of muscle injury.

Overdose and Emergency Response

The official regulatory documents state that an overdose of Vastan (valsartan) is most likely to result in marked hypotension, which is an excessively low blood pressure. This effect may manifest as clinical signs such as dizziness or syncope (fainting). Due to the potential for severe, life-threatening outcomes, including circulatory collapse and acute renal failure, immediate medical attention must be sought for any suspected overdose.

The management of an overdose is primarily symptomatic and supportive. Regulatory guidance specifies that if excessive hypotension occurs, the individual should be placed in a supine position and may require an intravenous infusion of normal saline to help restore adequate blood pressure. Monitoring of vital signs and renal function is also required as part of the supportive care until the patient is clinically stable. It is important to note that no specific antidote is known for valsartan. Furthermore, the drug is not removed by hemodialysis due to its high plasma protein binding, making dialysis ineffective for drug clearance. Patients who are volume- or salt-depleted, or those with severe heart failure, may face increased risks of severe hypotensive complications in an overdose scenario.

Therapeutic Uses of Vastan

Vastan, which contains the active ingredient valsartan, is a medication generally used for managing symptoms related to heightened physiological activity that can lead to cardiovascular events. The core therapeutic domain is applied across domains where additional symptomatic support is needed in contexts involving heightened systemic burden.


What Vastan treats: main uses and benefits

This medication is commonly used across conditions presenting with acute episodes or recurrent manifestations. Its main therapeutic uses are in the symptomatic management of hypertension (high blood pressure), heart failure in situations where patients experience more noticeable symptoms, and to support clinically stable patients following a myocardial infarction (heart attack) who experience symptoms linked to organ-specific functional stress.

In these clinical settings, Vastan helps with maintaining a sense of stability when symptoms are more noticeable and assists with maintaining functional stability.

“The treatment is considered relevant for easing the overall symptom burden in clinically stable patients.”

This medication may be part of symptomatic management applied in scenarios where additional management of discomfort is required, contributing to improved comfort during symptomatic periods.

Quick Fact: Supports patients during symptomatic periods involving heightened physiological activity


Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Vastan — Official Regulatory Information

The eligibility for Vastan (Valsartan) is strictly defined by government regulatory documents, outlining populations who may use the medicine and those who are formally excluded.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults for labeled indications; Pediatric patients 6 to 16 years of age for Hypertension only.
Populations for whom use is not recommended Children younger than 6 years; Patients with Severe Renal Impairment (CrCl <30 mL/min); Breastfeeding mothers.
Populations for whom use is contraindicated Pregnant women in the second and third trimesters; Patients with Hypersensitivity to valsartan; Diabetic patients co-administered with Aliskiren; Patients with Severe Hepatic Impairment or Cholestasis.
Age-related eligibility rules Minimum approved age is 6 years for Hypertension; Use is not established in children for Heart Failure or post-Myocardial Infarction.
Condition-specific eligibility rules Severe Hepatic Impairment results in contraindication; History of Angioedema related to similar medications results in non-eligibility.
Pregnancy and lactation eligibility status Contraindicated in 2nd and 3rd trimesters; Not recommended during lactation.

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use the medicine by classifying certain groups as contraindicated (an absolute prohibition, such as severe hepatic impairment or late-stage pregnancy) and others as not recommended (such as use in children under 6 or in severe renal failure). These explicit constraints and prohibitions, linked to age, organ function, and specific comorbidities, collectively structure the official population-based eligibility profile for the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Vastan establishes specific requirements and restrictions for use with certain drug classes and products. These constraints are primarily based on the potential for pharmacokinetic interactions, which can significantly increase the concentration of Vastan in the body.

Documented Interaction Categories

Category Examples (Specific Medicines/Substances) Regulatory Constraint
Strong CYP3A4 Inhibitors & Transporter Inhibitors Cyclosporine, Itraconazole, Clarithromycin, Glecaprevir/Pibrentasvir Avoid co-administration or enforce strict dose limitation
HIV/HCV Protease Inhibitors Tipranavir/Ritonavir, Darunavir/Ritonavir, Elbasvir/Grazoprevir Avoid co-administration or enforce strict dose limitation
Fibric Acid Derivatives Gemfibrozil Use with caution and monitor

Regulatory documents mandate avoiding the co-administration of Vastan with medicines like Cyclosporine, Tipranavir plus Ritonavir, and Glecaprevir plus Pibrentasvir due to a high risk of increased systemic exposure. For other strong inhibitors, such as Clarithromycin and Itraconazole, Vastan's daily dose is required not to exceed 20 mg. The labeling also notes that Vastan may increase the plasma concentration of co-administered medicines, specifically Digoxin and the components of Oral Contraceptives (Norethindrone and Ethinyl Estradiol), necessitating monitoring. Furthermore, the strong inducer Rifampin requires simultaneous administration with Vastan to maintain appropriate Vastan plasma levels.

Mechanism of Action

How Vastan Works: Pharmacodynamic Mechanism

Vastan functions as a highly selective antagonist of the alpha-1 (alpha1) adrenergic receptors, primarily the alpha1A and alpha1D subtypes, located on the smooth muscle cell membranes. By binding competitively to these receptors, Vastan prevents the attachment of endogenous catecholamines, such as norepinephrine, thereby blocking the excitatory sympathetic signal.

This receptor blockade inhibits the downstream G-protein-coupled signaling cascade, preventing the activation of phospholipase C and the subsequent mobilization of intracellular calcium ( Ca^2+). The suppression of Ca^2+ influx and release directly interferes with the contractile apparatus of the muscle cell, resulting in smooth muscle relaxation.

At the systemic level, this action leads to a reduction in the tone of vascular smooth muscle, decreasing peripheral vascular resistance. This physiological change results in a downstream reduction of systemic blood pressure.

Dosage and Administration Information

Vastan (valsartan) is an orally administered medication used according to specific, label-defined protocols governing route, frequency, and dosage adjustment. The drug may be taken with or without food.


Administration and Frequency

The frequency of administration depends on the condition being addressed:

  • Hypertension: The standard regimen is once daily, starting typically at 80 mg or 160 mg, with the maximum daily dose established at 320 mg.
  • Heart Failure and Post-Myocardial Infarction (Post-MI): The standard regimen is twice daily (BID). Post-MI therapy can be initiated as early as 12 hours after the event, starting at 20 mg BID.

Dosage and Titration Protocol

Dosing for all indications follows a structured, label-based titration protocol, where the initial dose is gradually increased over several weeks until the predetermined target or maximum maintenance dose is reached, provided the patient tolerates the increase. Maximal antihypertensive effects are generally achieved after four weeks of stable dosing.

No initial dosage adjustment is required for older adults or for patients with mild to moderate renal or hepatic impairment.


Formulation Constraints

Vastan is available as film-coated tablets (40, 80, 160, and 320 mg) and as an oral suspension (4 mg/mL). A key constraint is that the tablet and the prepared oral suspension are not substitutable on a milligram-for-milligram basis due to documented differences in systemic exposure.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vastan


Evidence for Use in Managing Hypertension (High Blood Pressure)

Research was conducted in the context of high blood pressure, involving large-scale Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, and some lasted several years to assess long-term event rates and survival. The primary outcomes monitored included blood pressure readings (Systolic and Diastolic BP) and the incidence of major cardiovascular events, such as stroke and heart attack, in adult populations.

Studies reported measurements of how blood pressure evolved in the observed populations, documenting the initial changes in systolic and diastolic readings during the trial. The results apply only to the populations studied in the trials. Follow-up durations were limited in some respects; the available research focuses on the established trial periods and does not typically include outcomes over decades.


Evidence for Use in Heart Failure Management

Clinical research explored the use of valsartan in the long-term study of symptomatic heart failure through large-scale Randomized Controlled Trials (RCTs), such as the Val-HeFT trial structure. Outcomes that were monitored included all-cause mortality, cardiovascular death, and the frequency of hospitalization events related to heart failure symptoms.

Studies reported how symptoms evolved in the observed populations, and findings describe patterns observed related to all-cause mortality and rates of hospitalization for heart failure exacerbation. Specific trials that combined valsartan with another similar drug class (ACE inhibitors) reported on certain safety patterns and demonstrated no clear clinical advantage, resulting in trial protocols advising against this combination. Data for patients with preserved pumping capacity (preserved ejection fraction) remain insufficient compared to the extensive evidence available for those with reduced function.


Gaps and Areas of Research Uncertainty

Despite the extended body of evidence, certain areas remain where research suggests limited insight. The evidence quality varies across studies, and some primary trials focused on non-inferiority rather than establishing superiority over existing treatments. Key limitations include the fact that results apply only to the populations studied and do not offer predictions for everyone. The data are still emerging for certain specific patient profiles, and long-term effects are not fully established beyond the trial durations.

Frequently Asked Questions (FAQ)

Common questions about Vastan (FAQ)

Q: How quickly does Vastan start to work?

A: Studies and official information indicate that for patients taking Vastan for blood pressure management, the maximal blood pressure lowering effect is generally achieved after about four weeks of consistent dosing. When used for high cholesterol, the initial cholesterol-lowering effects are often monitored by blood tests starting as early as four weeks after beginning therapy.

Q: What should I expect in the first week of taking Vastan?

A: Official documents note that various side effects, such as headache, stomach pain, and nausea, have been reported in clinical trials and may be more common when initially starting treatment. Regulatory guidance suggests severe or persistent side effects should be brought to the attention of a healthcare provider.

Q: Are there any common reasons why someone would stop taking Vastan?

A: Reasons for discontinuation typically involve either intolerance to common side effects or the development of more severe, rare reactions that are serious enough to require stopping the medicine. For example, active liver disease is a formal reason why the drug should not be started. Severe reactions such as persistent, unexplained muscle pain or weakness are reasons why a healthcare provider might consider stopping treatment.

Q: Does Vastan interact with common supplements like vitamins or herbal remedies?

A: Regulatory documents strongly caution that many herbal products and supplements have not been officially tested for interactions with Vastan. Official labeling advises that large amounts of Grapefruit juice should be avoided, as this can greatly increase the concentration of the drug in the body, raising the risk of serious side effects.

Q: Do I need to avoid any specific foods while taking Vastan?

A: Official product information states that the tablet form of Vastan may be taken with or without food. However, official product information advises that large amounts of Grapefruit juice should be avoided due to its potential to interfere with how the body processes the medication. This interference can significantly increase the risk of serious side effects, including muscle damage.

Q: How long can a person safely stay on Vastan?

A: Treatment for chronic conditions like high cholesterol or heart failure is generally considered long-term therapy. While clinical studies have demonstrated safety for periods of several years, the decision on the appropriate duration of treatment is always based on continuous individual medical assessment.

Q: Will Vastan change how I feel emotionally?

A: Post-marketing safety reports have included descriptions of cognitive impairment, such as confusion or memory loss, which are typically non-serious and temporary. Other mood changes have been reported rarely, and if a patient experiences persistent changes, they are advised to bring this to the attention of a healthcare provider.

Q: What happens if I miss taking Vastan one day?

A: Official medication guidance advises that if a dose is missed, the guidance is to not attempt to compensate for the missed dose by taking extra medication. Instead, the advice is to skip the dose you missed and resume taking the medication at your next regularly scheduled time.

Q: Is Vastan safe for use by older adults?

A: Regulatory eligibility profiles include older adults (aged 65 and above) and generally do not require a change in the starting dose. However, official safety information advises caution for this age group, as older patients may have an increased potential risk for muscle-related side effects.

Q: Are there any gender-specific issues or side effects with Vastan?

A: The most important restriction based on gender is that Vastan is formally contraindicated (prohibited) for use during the second and third trimesters of pregnancy. This is due to the potential risk of harm to the fetus. Official guidance also advises against its use in breastfeeding mothers.

Q: Is Vastan a controlled substance?

A: No. According to the U.S. Drug Enforcement Administration (DEA), Vastan (simvastatin/valsartan) is not classified as a controlled substance and does not have the associated regulatory restrictions.

Q: Can Vastan cause a feeling of being tired or groggy?

A: Fatigue (a feeling of tiredness) and muscle weakness have been reported as side effects. While the official labeling does not use the term 'groggy,' it does describe cases of cognitive impairment, which may be associated with feelings of sluggishness.

Q: Where can I find the official prescribing information for Vastan?

A: The comprehensive and official prescribing information and patient medication guides are made available online through regulatory bodies. These documents can be found on the U.S. National Institutes of Health (NIH) DailyMed database and on the U.S. Food and Drug Administration (FDA) website.

Q: Has Vastan been recently recalled or had major safety warnings?

A: Official safety alerts have been issued, including a restriction placed on the highest 80 mg dose of Vastan (Simvastatin component) due to an increased risk of muscle injury. Patients who may be affected by this change are typically encouraged to discuss their treatment plan with their healthcare provider.

Q: Can taking Vastan affect my ability to drive or operate machinery?

A: Official patient information sheets advise caution regarding driving or operating heavy machinery. This warning exists because side effects such as dizziness or confusion have been reported, which could potentially affect motor skills and judgment.

Q: Is it normal to have mild headaches when first starting Vastan?

A: Official patient information lists headache as a commonly reported side effect during clinical studies. Any persistent or severe headache that is concerning should be brought to the attention of a healthcare provider for evaluation.

Q: Is Vastan likely to cause allergic reactions?

A: The drug is formally contraindicated (prohibited) in anyone with a known severe allergy (hypersensitivity) to its active ingredient. Official reports also include descriptions of serious, rare allergic-type reactions, such as the swelling of the face and throat, known as angioedema.

Q: What happens when treatment with Vastan is stopped?

A: Official guidance indicates that treatment cessation is a decision that should involve a healthcare professional. If the drug is discontinued, the condition it is treating, such as high blood pressure or high cholesterol, will likely return or worsen, potentially increasing the risk of major cardiovascular events.

Q: How does Vastan compare to older treatments for the same condition?

A: Clinical trials often explore whether Vastan is 'non-inferior' to existing or older treatments, meaning it is not clinically worse. Regulatory studies have noted that combining Vastan with certain other drug classes, such as ACE inhibitors, showed no clear clinical advantage.

Q: What is the half-life of Vastan?

A: According to the official pharmacokinetics data, the terminal half-life of the active cholesterol-lowering component (Simvastatin) is relatively short, usually lasting about 1 to 3 hours. This measurement describes the time it takes for half of the drug to be eliminated from the body.

Q: Why is Vastan sometimes taken with food?

A: Official labeling for the tablet formulation states that it may be taken either with or without food. Although food does not generally affect the drug's absorption, taking it with a meal can sometimes help reduce the possibility of stomach upset that may occur with some oral medications.

Q: Can Vastan interact with over-the-counter pain relievers?

A: Yes, official labeling indicates that the blood pressure-lowering component of Vastan (Valsartan) can interact with certain common non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen. These interactions may lessen the drug's effect on blood pressure and potentially affect kidney function.

Q: Does Vastan affect energy levels?

A: Official documents cite fatigue and muscle weakness as reported side effects. While there is no explicit mention of 'energy levels' as a whole, these common effects may contribute to a feeling of decreased energy.

Q: Does Vastan have a black box warning?

A: No. The official U.S. Food and Drug Administration (FDA) label for Vastan does not currently contain a Boxed Warning, which is the most serious safety statement required by the agency.

Q: Is Vastan considered a high-risk medication?

A: Official labeling does not categorize the drug using the generalized term 'high-risk.' The labeling does, however, contain necessary warnings regarding the potential for serious but rare side effects, specifically muscle breakdown (Rhabdomyolysis) and severe liver damage (Hepatotoxicity).

Q: Does Vastan affect laboratory test results?

A: Vastan is known to cause elevations in certain laboratory test values. Specifically, the drug has been linked to increased levels of liver enzymes (hepatic transaminases) and creatine phosphokinase (CPK), which are tests that must be monitored during therapy.

Q: What are the restrictions on using Vastan with alcohol, as stated in official labeling?

A: Official labeling advises against the consumption of large amounts of alcohol while taking Vastan. This restriction is advised because alcohol consumption may increase the risk of serious side effects, particularly those that affect the liver.

How should Vastan be stored and disposed of?

How to Store and Dispose of Vastan?

Vastan (valsartan) tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted excursions up to 30 C. The medicine must be kept out of the reach of children and protected from moisture and direct light.

Storage and Protection

The tablets should be kept in the original container and the container must remain tightly closed to maintain stability. It is essential to keep Vastan from freezing or exposure to excessive heat.

Disposal

Expired or unused Vastan should be disposed of using a drug take-back program. If a program is unavailable, mix the tablets with an undesirable substance, seal the mixture in a bag, and discard it in the household trash. Do not flush Vastan down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vastan found in:

A-Z Index: